Literature DB >> 8113631

Treatment of advanced pancreatic cancer with high-dose octreotide.

H Friess, M Büchler, M Ebert, P Malfertheiner, H J Dennler, H G Beger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8113631     DOI： 10.1007/BF02784939

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN： 0169-4197


× No keyword cloud information.
  9 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Carcinoma of the exocrine pancreas: a sex hormone responsive tumour?

Authors:  B A Greenway
Journal:  Br J Surg       Date:  1987-06       Impact factor: 6.939

Review 3.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

4.  Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.

Authors:  H Friess; M Büchler; C Beglinger; A Weber; J Kunz; K Fritsch; H J Dennler; H G Beger
Journal:  Pancreas       Date:  1993-09       Impact factor: 3.327

5.  On the receiving end. IV: Validation of quality of life indicators.

Authors:  P Butow; A Coates; S Dunn; J Bernhard; C Hürny
Journal:  Ann Oncol       Date:  1991-09       Impact factor: 32.976

6.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study.

Authors:  L Canobbio; F Boccardo; D Cannata; P Gallotti; R Epis
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

7.  Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.

Authors:  J C Reubi; U Horisberger; C E Essed; J Jeekel; J G Klijn; S W Lamberts
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

8.  Evaluation of receptors for somatostatin in various tumors using different analogs.

Authors:  G Srkalovic; R Z Cai; A V Schally
Journal:  J Clin Endocrinol Metab       Date:  1990-03       Impact factor: 5.958

9.  Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

Authors:  J G Klijn; A M Hoff; A S Planting; J Verweij; T Kok; S W Lamberts; H Portengen; J A Foekens
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640
  9 in total
  4 in total

Review 1.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

2.  Phospholipase A2 isoforms are altered in chronic pancreatitis.

Authors:  M Kashiwagi; H Friess; W Uhl; H Graber; R Duarte; A Zimmermann; M W Büchler
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

Review 3.  Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.

Authors:  B Fazeny; M Baur; M Prohaska; M Hudec; M Kremnitzer; S Meryn; H Huber; T Grunt; A Tuchmann; C Dittrich
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 4.  Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.

Authors:  H Friess; M Gassmann; M W Büchler
Journal:  Int J Pancreatol       Date:  1997-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.